Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

1954 - Diagnostic and therapeutic strategies for elderly patients with advanced Non-Small cell lung cancer (NSCLC): results from an EORTC pan-european survey


09 Sep 2017


Poster display session


Cancers in Adolescents and Young Adults (AYA);  Geriatric Oncology;  Non-Small Cell Lung Cancer


Matteo Giaj Levra


Annals of Oncology (2017) 28 (suppl_5): v460-v496. 10.1093/annonc/mdx380


M. Giaj Levra1, J. Menis2, A. Luciani3, E. De Maio4, B. Hasan4, T. Berghmans5, M.A. Massiani6, M. De Waele7, A. Dingemans8, J. Donckele4, C. Faivre-Finn9, N. Girard10, L. Greillier11, S. Lantuéjoul12, M. O'Brien13, M. Reck14, K. Tryfonidis4, H. Wildiers15, B. Besse2, S. Novello16

Author affiliations

  • 1 Chest Department, CHU Grenoble - Hopital Michallon, 38043 - La Tronche/FR
  • 2 Cancer Medicine, Institut de Cancérologie Gustave Roussy, 94805 - Villejuif/FR
  • 3 Medical Oncology, Azienda Ospedaliera S. Paolo, 20142 - Milano/IT
  • 4 Eortc, European Organisation for Research and Treatment of Cancer, 1200 - Brussels/BE
  • 5 Oncology, Institute Jules Bordet, 1000 - Brussels/BE
  • 6 Oncology, Institut Curie, Paris/FR
  • 7 Oncology, U.Z.A. University Hospital Antwerp, 2650 - Edegem/BE
  • 8 Pulmonology, Maastricht University Medical Center, Maastricht/NL
  • 9 Radiotherapy, The Christie NHS Foundation Trust, M20 4BX - Manchester/GB
  • 10 Pneumologie, Hôpital Louis Pradel-Hospices Civils de Lyon, 69500 - Bron/FR
  • 11 Pneumologie, Hopital St. Marguerite Assistance Publique Hopitaux de Marseille, 13009 - Marseille/FR
  • 12 Pathology Department, CHU Grenoble - Hopital Michallon, 38043 - La Tronche/FR
  • 13 Oncology, Royal Marsden Hospital NHS Foundation Trust, SW3 6JJ - London/GB
  • 14 Thoracic Oncology, Krankenhaus Grosshansdorf, 22927 - Grosshansdorf/DE
  • 15 General Medical Oncology, University Hospitals Leuven, Leuven/BE
  • 16 Oncology, University of Turin, Orbassano/IT


Abstract 1954


The EORTC Lung Cancer Group (LCG) and the Elderly Task Force (ETF) developed a pan-european survey that aims to provide an overview of the management and treatment strategies for elderly patients (pts) diagnosed with advanced NSCLC, as well as to identify potential needs and scientific pending questions that could be addressed in new trials.


An electronic 13-topic survey explaining the study purpose was developed and sent to all EORTC LCG and ETF members. The 25-items included multiple-choice and open-ended questions requesting the following information on general demographics (6 items), pts population (3 items) and diagnostic, treatment preferences and outcomes (4 items). Elderly pts were defined as those older than 70 years.


Sixty-two individual sites, from 19 countries, completed the online questionnaire. In 42 centers (67.7%) there is no dedicated team for the management and treatment of elderly pts; on the other hand, only in 2 centers (3.2%) pts with suspected NSCLC are not discussed by a multidisciplinary board. Notably, oncogeriatric assessment is routinely performed in 17 (27.4%) centers; G8, CGA or both scales are the preferred evaluation tools (35.3%, 23.6% and 11.8% respectively). In fit pts, the preferred first-line chemotherapy regimens are Carboplatin (CBDCA)-Pemetrexed (PEM) 19 (31.7%), CBDCA-Paclitaxel (PAC) 15 (24.2%), Cisplatin (CDDP)-PEM 14 (22.6%), CBDCA-Gemcitabine (GEM) 10 (16%), other 3 (4.8%). In the second line setting the preferred treatments are Nivolumab 30 (45.5%), PEM 11 (16.7%), Docetaxel 9 (13.6%), PAC 8 (12.1%), GEM 4 (6.1%), Erlotinib 4 (6.1%); while PEM 15 (24.2%), Nivolumab 13 (20.1%), PAC 9 (14.5%), Docetaxel 6 (9.7%), GEM 6 (9.7%), other 11 (17.7%) represent a second level option.


The survey provides an overview of the clinical practice in the management of elderly patients with advanced NSCLC, summarizing relevant and updated background for the possible development of future collaborative trials. In this survey, different treatment regimens are used by different centers, and geriatric assessment is used heterogeneously, reflecting the lack of a “standardized” approach and the need for further research in this area.

Clinical trial identification

Legal entity responsible for the study





All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.